Autopsy report · NCT05065567

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

“Lost too many patients to follow up, unable to enroll enough patients”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 3 months before it stopped.
• 32 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Corewell Health South

Sponsor type

University, hospital or other

Conditions

Cyclic Vomiting Syndrome

Interventions

Droperidol; Haloperidol; Ondansetron 8mg

Participants

32

Sites

1

Countries

United States

Trials that died the same way

• Growth Hormone Therapy for Wasting in Cystic Fibrosis
  “Poor enrollment, patients were lost to follow up” (83% match in meaning)
• The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision
  “Unable to enroll more patients” (81% match in meaning)
• Safety and Efficacy of Delayed Manipulation After Xiaflex Treatment in Subjects With Dupuytren's Contracture
  “difficulty enrolling additional patients” (78% match in meaning)
• Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")
  “difficulties of recruitment, high number of patients lost to follow-up” (77% match in meaning)
• Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
  “no enough enrolled patients” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.